Chlorproguanil hydrochloride-dapsone-artesunate
Encyclopedia
Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006.
It consists of chlorproguanil hydrochloride, dapsone
, and artesunate
. (It can also be interpreted as Lapdap
+artesunate).
It is being compared against artemether-lumefantrine (Coartem
) and against chlorproguanil-dapsone Lapdap
. This drug is being developed in collaboration between GlaxoSmithKline
, UNICEF, the World Bank
, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine
, and the London School of Hygiene and Tropical Medicine.
It consists of chlorproguanil hydrochloride, dapsone
Dapsone
Dapsone is a medication most commonly used in combination with rifampicin and clofazimine as multidrug therapy for the treatment of Mycobacterium leprae infections . It is also second-line treatment for prophylaxis against Pneumocystis pneumonia caused by Pneumocystis jiroveci Dapsone...
, and artesunate
Artesunate
Artesunate is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection...
. (It can also be interpreted as Lapdap
Lapdap
Chlorproguanil/dapsone was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency....
+artesunate).
It is being compared against artemether-lumefantrine (Coartem
Coartem
The combination artemether/lumefantrine is an artemisinin-based combination therapy indicated for the treatment of acute uncomplicated plasmodium falciparum malaria. Coartem is produced by the Swiss pharmaceutical company, Novartis.Artemether is a derivative of artemisinin, and lumefantrine is...
) and against chlorproguanil-dapsone Lapdap
Lapdap
Chlorproguanil/dapsone was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency....
. This drug is being developed in collaboration between GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom...
, UNICEF, the World Bank
World Bank Group
The World Bank Group is a family of five international organizations that makes leveraged loans, generally to poor countries.The Bank came into formal existence on 27 December 1945 following international ratification of the Bretton Woods agreements, which emerged from the United Nations Monetary...
, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine
Liverpool School of Tropical Medicine
The Liverpool School of Tropical Medicine is a research and teaching institution focused on neglected tropical diseases and the control of diseases caused by poverty. It is a registered charity affiliated to the University of Liverpool...
, and the London School of Hygiene and Tropical Medicine.